HUE041941T2 - Új kromon oxim-származék és metabotróp glutamát receptorok allosztérikus modulátoraként történõ alkalmazása - Google Patents

Új kromon oxim-származék és metabotróp glutamát receptorok allosztérikus modulátoraként történõ alkalmazása

Info

Publication number
HUE041941T2
HUE041941T2 HUE15770814A HUE15770814A HUE041941T2 HU E041941 T2 HUE041941 T2 HU E041941T2 HU E15770814 A HUE15770814 A HU E15770814A HU E15770814 A HUE15770814 A HU E15770814A HU E041941 T2 HUE041941 T2 HU E041941T2
Authority
HU
Hungary
Prior art keywords
new
metabotropic glutamate
glutamate receptors
allosteric modulator
oxime derivative
Prior art date
Application number
HUE15770814A
Other languages
English (en)
Hungarian (hu)
Inventor
Delphine Charvin
Baptiste Manteau
Vincent Pomel
François Conquet
Original Assignee
Prexton Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prexton Therapeutics Sa filed Critical Prexton Therapeutics Sa
Publication of HUE041941T2 publication Critical patent/HUE041941T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE15770814A 2014-08-27 2015-08-27 Új kromon oxim-származék és metabotróp glutamát receptorok allosztérikus modulátoraként történõ alkalmazása HUE041941T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27

Publications (1)

Publication Number Publication Date
HUE041941T2 true HUE041941T2 (hu) 2019-06-28

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15770814A HUE041941T2 (hu) 2014-08-27 2015-08-27 Új kromon oxim-származék és metabotróp glutamát receptorok allosztérikus modulátoraként történõ alkalmazása

Country Status (26)

Country Link
US (3) US10017521B2 (enExample)
EP (3) EP3186257B1 (enExample)
JP (1) JP6430015B2 (enExample)
KR (1) KR101870589B1 (enExample)
CN (2) CN110343118A (enExample)
AU (1) AU2015308438B2 (enExample)
CA (1) CA2956191C (enExample)
CY (1) CY1121352T1 (enExample)
DK (1) DK3186257T3 (enExample)
ES (1) ES2714073T3 (enExample)
HR (1) HRP20190343T1 (enExample)
HU (1) HUE041941T2 (enExample)
IL (1) IL250287B (enExample)
LT (1) LT3186257T (enExample)
MA (3) MA48048A (enExample)
ME (1) ME03339B (enExample)
MX (1) MX369643B (enExample)
NZ (1) NZ728853A (enExample)
PL (1) PL3186257T3 (enExample)
PT (1) PT3186257T (enExample)
RS (1) RS58592B1 (enExample)
RU (1) RU2672569C2 (enExample)
SI (1) SI3186257T1 (enExample)
SM (1) SMT201900152T1 (enExample)
TR (1) TR201903332T4 (enExample)
WO (1) WO2016030444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190343T1 (hr) * 2014-08-27 2019-05-31 Prexton Therapeutics Sa Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata
US10532057B2 (en) * 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US20220089609A1 (en) 2018-07-26 2022-03-24 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
WO2007011701A1 (en) 2005-07-15 2007-01-25 Transform Pharmaceuticals, Inc. Novel hydrochloride salts of levodopa
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
EP2181110A2 (en) 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2493871B1 (en) * 2009-10-30 2014-09-03 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
NZ767139A (en) * 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
US20140349994A1 (en) * 2012-01-18 2014-11-27 Addex Pharma S.A. Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
HRP20190343T1 (hr) 2014-08-27 2019-05-31 Prexton Therapeutics Sa Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata
US10532057B2 (en) 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia

Also Published As

Publication number Publication date
ME03339B (me) 2019-10-20
US10017521B2 (en) 2018-07-10
AU2015308438A1 (en) 2017-03-02
CN106715444B (zh) 2019-07-12
LT3186257T (lt) 2019-04-25
NZ728853A (en) 2018-04-27
CA2956191A1 (en) 2016-03-03
JP6430015B2 (ja) 2018-11-28
HRP20190343T1 (hr) 2019-05-31
CY1121352T1 (el) 2020-05-29
EP3186257B1 (en) 2019-02-06
MA48048A (fr) 2020-02-12
RU2017109818A3 (enExample) 2018-10-01
CA2956191C (en) 2020-01-28
KR101870589B1 (ko) 2018-06-25
WO2016030444A1 (en) 2016-03-03
SI3186257T1 (sl) 2019-07-31
MX369643B (es) 2019-11-15
PT3186257T (pt) 2019-03-27
KR20170042624A (ko) 2017-04-19
DK3186257T3 (en) 2019-04-01
US20170253613A1 (en) 2017-09-07
TR201903332T4 (tr) 2019-03-21
EP3502115A1 (en) 2019-06-26
RU2672569C2 (ru) 2018-11-16
US20180291034A1 (en) 2018-10-11
MA52702A (fr) 2021-03-31
IL250287B (en) 2020-02-27
CN106715444A (zh) 2017-05-24
MA40530A (fr) 2017-07-05
JP2017525776A (ja) 2017-09-07
EP3696183A1 (en) 2020-08-19
AU2015308438B2 (en) 2018-12-13
CN110343118A (zh) 2019-10-18
US10442818B2 (en) 2019-10-15
ES2714073T3 (es) 2019-05-27
US20200024285A1 (en) 2020-01-23
MX2017002429A (es) 2017-08-02
RU2017109818A (ru) 2018-10-01
RS58592B1 (sr) 2019-05-31
SMT201900152T1 (it) 2019-05-10
EP3186257A1 (en) 2017-07-05
PL3186257T3 (pl) 2019-07-31
IL250287A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
NL301128I2 (nl) Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
LT3322701T (lt) Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
NL301208I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
UA37801S (uk) Пристрій для інтраназального введення ліків
HUE057120T2 (hu) 3-izoxalidonok alkalmazása szelektív herbicidként
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3615527T3 (da) Nye azaquinolin-derivater
UA31326S (uk) Наконечник курильного приладдя
BR112016003413A2 (pt) prancha ergometrica de uma esteira ergometrica e esteira ergometrica
HUE040274T2 (hu) Heteroarilamidok a proteinaggregáció inhibitoraiként
BR112016016017A2 (pt) métodos para gerar um fluxo de atividades
HRP20190147T1 (hr) Benzoksazinon amidi kao modulatori mineralokortikodnih receptora
DK3143018T3 (da) Carboxamidderivater
DK3707143T3 (da) Nye analoger som androgenreceptor- og glucorticoidreceptor-modulatorer
SI3226888T1 (sl) Dajanje selektivnega zaviralca signalizacije IL-6-trans
LT3347349T (lt) Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai
HUE058726T2 (hu) Új nilotinib sók és azok polimorfjai
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
HUE041941T2 (hu) Új kromon oxim-származék és metabotróp glutamát receptorok allosztérikus modulátoraként történõ alkalmazása
BR112016026725A2 (pt) Derivados de aminoéster
IL251230A0 (en) Converted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
EP3206637A4 (en) An intrauterine device with a restricted movement of a string knot
PL3431106T3 (pl) Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
HUE071186T2 (hu) Trazodon és gabapentin kombinációja fájdalom kezelésére